Zydus Lifesciences completes subscription and joint venture with Zydus Sunshine
Zydus Lifesciences · Pharmaceuticals & Biotechnology
Key highlights
- Subscription of 50% equity in Zydus Sunshine Lifesciences (Private) Limited completed on Nov 11, 2026
- Joint venture between Zydus Lifesciences and Sunshine Healthcare Lanka Limited established, holding equal 50:50 shares
- Completion delayed due to office holidays; was initially expected within 90 working days, extended to December 2026
Original filing
Announcement under Regulation 30 (LODR)-Updates on Joint Venture
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Zydus Lifesciences
- Acquisition / mergerMajor development· Adverse for the businessZydus Lifesciences reports unaudited results for quarter ended September 30, 2026
- Acquisition / mergerNotableZydus Lifesciences completes acquisition of Sterling Biotech's API business
- Acquisition / mergerNotableZydus Lifesciences completes acquisition of Assertio Holdings on June 16, 2026
- Acquisition / mergerNotableZydus Lifesciences completes merger making Asserto a wholly owned subsidiary
- Dividend / buyback / bonusNotableZydus Lifesciences Q4 FY26 adjusted net profit up 14.6%; buyback up to Rs. 11,000 mn
Other acquisition / merger filings this fortnight
- Abans Financial Services announces CEO resignation, new director appointment, and subsidiary incorporation
- Alivus Life Sciences acquires 65.01% stake in IQGEN-X Pharma
- Indo Borax reports H1FY27 consolidated operating income up 16.0% to Rs 129.29 crore
- Manoj Agrawal Acquires 1.00 Crore Shares in Cubical Financial Services Limited
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.